↓ Skip to main content

Retinoblastoma

Overview of attention for article published in Orphanet Journal of Rare Diseases, August 2006
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
5 news outlets
twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
146 Dimensions

Readers on

mendeley
220 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Retinoblastoma
Published in
Orphanet Journal of Rare Diseases, August 2006
DOI 10.1186/1750-1172-1-31
Pubmed ID
Authors

Isabelle Aerts, Livia Lumbroso-Le Rouic, Marion Gauthier-Villars, Hervé Brisse, François Doz, Laurence Desjardins

Abstract

Retinoblastoma is a rare eye tumor of childhood that arises in the retina. It is the most common intraocular malignancy of infancy and childhood; with an incidence of 1/15,000-20,000 live births. The two most frequent symptoms revealing retinoblastoma are leukocoria and strabismus. Iris rubeosis, hypopyon, hyphema, buphthalmia, orbital cellulites and exophthalmia may also be observed. Sixty per cent of retinoblastomas are unilateral and most of these forms are not hereditary (median age at diagnosis two years). Retinoblastoma is bilateral in 40% of cases (median age at diagnosis one year). All bilateral and multifocal unilateral forms are hereditary. Hereditary retinoblastoma constitutes a cancer predisposition syndrome: a subject constitutionally carrying an RB1 gene mutation has a greater than 90% risk of developing retinoblastoma but is also at increased risk of developing other types of cancers. Diagnosis is made by fundoscopy. Ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) scans may contribute to diagnosis. Management of patients with retinoblastoma must take into account the various aspects of the disease: the visual risk, the possibly hereditary nature of the disease, the life-threatening risk. Enucleation is still often necessary in unilateral disease; the decision for adjuvant treatment is taken according to the histological risk factors. Conservative treatment for at least one eye is possible in most of the bilateral cases. It includes laser alone or combined with chemotherapy, cryotherapy and brachytherapy. The indication for external beam radiotherapy should be restricted to large ocular tumors and diffuse vitreous seeding because of the risk of late effects, including secondary sarcoma. Vital prognosis, related to retinoblastoma alone, is now excellent in patients with unilateral or bilateral forms of retinoblastoma. Long term follow-up and early counseling regarding the risk of second primary tumors and transmission should be offered to retinoblastoma patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 220 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
Netherlands 1 <1%
Pakistan 1 <1%
South Africa 1 <1%
Portugal 1 <1%
India 1 <1%
Egypt 1 <1%
Peru 1 <1%
Philippines 1 <1%
Other 0 0%
Unknown 210 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 49 22%
Student > Master 27 12%
Student > Postgraduate 24 11%
Student > Ph. D. Student 24 11%
Researcher 13 6%
Other 30 14%
Unknown 53 24%
Readers by discipline Count As %
Medicine and Dentistry 87 40%
Biochemistry, Genetics and Molecular Biology 27 12%
Agricultural and Biological Sciences 23 10%
Engineering 5 2%
Immunology and Microbiology 4 2%
Other 19 9%
Unknown 55 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2020.
All research outputs
#741,221
of 19,508,584 outputs
Outputs from Orphanet Journal of Rare Diseases
#60
of 2,134 outputs
Outputs of similar age
#6,007
of 169,485 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#1
of 12 outputs
Altmetric has tracked 19,508,584 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,134 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,485 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.